ICU Medical, Inc. (NASDAQ:ICUI) Receives $173.00 Average Price Target from Analysts

Shares of ICU Medical, Inc. (NASDAQ:ICUI) have received an average rating of “Moderate Buy” from the five analysts that are currently covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $173.00.

Several equities research analysts recently issued reports on ICUI shares. StockNews.com raised shares of ICU Medical from a “hold” rating to a “buy” rating in a research report on Wednesday. Needham & Company LLC reissued a “hold” rating on shares of ICU Medical in a research report on Wednesday, November 13th. KeyCorp lifted their price target on shares of ICU Medical from $198.00 to $209.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 13th. Raymond James raised their price target on shares of ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a research report on Thursday, September 12th. Finally, Jefferies Financial Group started coverage on shares of ICU Medical in a research report on Monday, October 14th. They set a “hold” rating and a $183.00 price target on the stock.

Insider Transactions at ICU Medical

In other ICU Medical news, VP Daniel Woolson sold 2,502 shares of the firm’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $163.22, for a total value of $408,376.44. Following the sale, the vice president now owns 13,107 shares of the company’s stock, valued at $2,139,324.54. This trade represents a 16.03 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Vivek Jain sold 12,000 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $163.46, for a total transaction of $1,961,520.00. Following the transaction, the chief executive officer now owns 104,593 shares in the company, valued at approximately $17,096,771.78. The trade was a 10.29 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 38,502 shares of company stock worth $6,573,496 in the last 90 days. 6.70% of the stock is owned by insiders.

Institutional Trading of ICU Medical

Large investors have recently made changes to their positions in the business. SG Americas Securities LLC grew its stake in shares of ICU Medical by 441.7% during the second quarter. SG Americas Securities LLC now owns 5,818 shares of the medical instruments supplier’s stock worth $691,000 after purchasing an additional 4,744 shares during the period. Sei Investments Co. boosted its position in ICU Medical by 52.1% during the first quarter. Sei Investments Co. now owns 28,586 shares of the medical instruments supplier’s stock valued at $3,068,000 after purchasing an additional 9,793 shares during the last quarter. Silvercrest Asset Management Group LLC grew its stake in shares of ICU Medical by 109.4% in the first quarter. Silvercrest Asset Management Group LLC now owns 278,436 shares of the medical instruments supplier’s stock valued at $29,882,000 after buying an additional 145,485 shares in the last quarter. Vanguard Group Inc. raised its position in ICU Medical by 0.5% during the first quarter. Vanguard Group Inc. now owns 2,452,720 shares of the medical instruments supplier’s stock worth $263,226,000 after acquiring an additional 11,991 shares in the last quarter. Finally, Savant Capital LLC bought a new stake in shares of ICU Medical in the 2nd quarter valued at about $431,000. Institutional investors own 96.10% of the company’s stock.

ICU Medical Trading Down 1.2 %

Shares of ICUI opened at $167.59 on Monday. ICU Medical has a 1-year low of $82.82 and a 1-year high of $196.26. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.29 and a quick ratio of 1.03. The firm has a 50 day simple moving average of $176.54 and a 200-day simple moving average of $144.46. The stock has a market cap of $4.10 billion, a price-to-earnings ratio of -36.67 and a beta of 0.66.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.